Selective estrogen receptor modulators (SERMs) are drugs that can specifically modulate the activity of bone specific isoforms of the estrogen receptor; thus, they trigger the beneficial effect of estrogens over bone without increasing the risk of breast and uterine cancer [98]. The gene discussed is ESR1; the disease is uterine cancer.